Table 1.
Demographic and baseline characteristics of the study population
| Characteristics | Add-on, n = 91 | Monotherapy, n = 104 | P value |
| Male (%) | 62 (68.1) | 76 (73.1) | 0.528 |
| Age in yr, mean ± SD | 38.11 ± 9.74 | 37.34 ± 11.01 | 0.529 |
| BMI in kg/cm2, mean ± SD | 21.97 ± 1.72 | 22.13 ± 1.05 | 0.157 |
| Mode of transmission | |||
| Vertical (%) | 36 (39.6) | 32 (30.8) | 0.229 |
| Others (%) | 55 (60.4) | 72 (69.2) | |
| HBsAg at week 0 | |||
| < 500 IU/mL (%) | 56 (61.5) | 49 (47.1) | 0.089 |
| 500-1000 IU/mL (%) | 17 (18.7) | 32 (30.8) | |
| 1000-1500 IU/mL (%) | 18 (19.8) | 23 (22.1) | |
| HBeAg status at enrollment | |||
| Negative (%) | 91 (100) | 104 (100) | _ |
| HBV DNA at enrollment | |||
| < 1.0 × 102 IU/ mL (%) | 91 (100.0) | 104 (100.0) | _ |
| ALT, IU/L, median (range) | 24 (8.0-73) | 27 (7-66) | 0.558 |
| AST, IU/L, median (range) | 23 (12-70) | 26 (14-66) | 0.212 |
| NA | |||
| ADV (%) | 10 (11.0) | 12 (11.5) | 0.395 |
| ETV (%) | 50 (54.9) | 66 (63.5) | |
| TDF (%) | 31 (34.1) | 26 (25.0) | |
| FibroScan value, kPa | |||
| mean ± SD | 4.2 ± 1.1 | 4.5 ± 1.2 | 0.824 |
SD: Standard deviation; BMI: Body mass index; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; HBV DNA: Hepatitis B virus-deoxyribonucleic acid; NA: Nucleos(t)ide analog; ADV: Adefovir dipivoxil; ETV: Entecavir; TDF: Tenofovir disoproxil fumarate; ALT: Alanine aminotransferase; AST: Aspartate transaminase.